Stock Track | Dynavax Soars 37.56% in Pre-Market as Sanofi Agrees to $2.2 Billion Acquisition

Stock Track

昨天

Dynavax Technologies (DVAX) surged 37.56% in pre-market trading after French pharmaceutical giant Sanofi announced it would acquire the company for $2.2 billion.

Sanofi will pay $15.50 per share in cash, a 39% premium over Dynavax's closing price on Tuesday. The deal, expected to close in Q1 2026, includes Dynavax's marketed adult hepatitis B vaccine (HEPLISAV-B) and a Phase 1/2 shingles candidate, bolstering Sanofi's vaccine portfolio.

The acquisition is fully funded by Sanofi's cash reserves and will not impact its 2025 financial outlook. Dynavax's board unanimously approved the deal, citing Sanofi's global scale as key to maximizing the value of its vaccine pipeline.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1147609075"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147609075\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147609075?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 18:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147609075","market":"sg","top_or_hot":-1,"title":"Stock Track | Dynavax Soars 37.56% in Pre-Market as Sanofi Agrees to $2.2 Billion Acquisition","media":"Stock Track","content":"<p>Dynavax Technologies (DVAX) surged 37.56% in pre-market trading after French pharmaceutical giant Sanofi announced it would acquire the company for $2.2 billion.</p><p>Sanofi will pay $15.50 per share in cash, a 39% premium over Dynavax's closing price on Tuesday. The deal, expected to close in Q1 2026, includes Dynavax's marketed adult hepatitis B vaccine (HEPLISAV-B) and a Phase 1/2 shingles candidate, bolstering Sanofi's vaccine portfolio.</p><p>The acquisition is fully funded by Sanofi's cash reserves and will not impact its 2025 financial outlook. Dynavax's board unanimously approved the deal, citing Sanofi's global scale as key to maximizing the value of its vaccine pipeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Dynavax Soars 37.56% in Pre-Market as Sanofi Agrees to $2.2 Billion Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Dynavax Soars 37.56% in Pre-Market as Sanofi Agrees to $2.2 Billion Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-24 18:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dynavax Technologies (DVAX) surged 37.56% in pre-market trading after French pharmaceutical giant Sanofi announced it would acquire the company for $2.2 billion.</p><p>Sanofi will pay $15.50 per share in cash, a 39% premium over Dynavax's closing price on Tuesday. The deal, expected to close in Q1 2026, includes Dynavax's marketed adult hepatitis B vaccine (HEPLISAV-B) and a Phase 1/2 shingles candidate, bolstering Sanofi's vaccine portfolio.</p><p>The acquisition is fully funded by Sanofi's cash reserves and will not impact its 2025 financial outlook. Dynavax's board unanimously approved the deal, citing Sanofi's global scale as key to maximizing the value of its vaccine pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DVAX","symbol_name":"德纳维制药","start_time":0,"source_url":"","article_id":"1147609075","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147609075","pubTimestamp":1766572240,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Dynavax Technologies (DVAX) surged 37.56% in pre-market trading after French pharmaceutical giant Sanofi announced it would acquire the company for $2.2 billion.Sanofi will pay $15.50 per share in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DVAX":"德纳维制药"},"translate_title":"个股追踪|赛诺菲同意22亿美元收购Dynavax盘前大涨37.56%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DVAX":1},"content_text":"Dynavax Technologies (DVAX) surged 37.56% in pre-market trading after French pharmaceutical giant Sanofi announced it would acquire the company for $2.2 billion.Sanofi will pay $15.50 per share in cash, a 39% premium over Dynavax's closing price on Tuesday. The deal, expected to close in Q1 2026, includes Dynavax's marketed adult hepatitis B vaccine (HEPLISAV-B) and a Phase 1/2 shingles candidate, bolstering Sanofi's vaccine portfolio.The acquisition is fully funded by Sanofi's cash reserves and will not impact its 2025 financial outlook. Dynavax's board unanimously approved the deal, citing Sanofi's global scale as key to maximizing the value of its vaccine pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}